Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research ...

Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications.

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Now Medicaid work requirements may be coming back soon as part of a proposed $2.3 trillion spending cut to the program. Trump ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

The FDA just slammed the door on its booming weight-loss drug business--but Hims & Hers has a bold new strategy.